Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PIQLF'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.42 Med: 23.44 Max: 42
Current: 8.67
During the past 11 years, the highest Price-to-Net-Cash Ratio of Proteomics International Laboratories was 42.00. The lowest was 5.42. And the median was 23.44.
PIQLF's Price-to-Net-Cash is ranked worse than 68.53% of 804
companies
in the Biotechnology industry
Industry Median: 5.335
vs PIQLF: 8.67
Proteomics International Laboratories (OTCPK:PIQLF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Proteomics International Laboratories Net Cash per Share Related Terms
Proteomics International Laboratories Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories Net Cash per Share Chart
PIQLF vs VRTX, REGN, ALNY: Net Cash per Share Comparison
For the Biotechnology subindustry, Proteomics International Laboratories's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteomics International Laboratories Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Proteomics International Laboratories's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Proteomics International Laboratories's Price-to-Net-Cash falls into.
Proteomics International Laboratories Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories (PIQLF) has a Net Cash per Share of $0.02 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Proteomics International Laboratories and its competitors. This is 100% below median its historical median of 23.44. Over the past decade, Proteomics International Laboratories' Net Cash per Share has ranged from 5.42 to 42.00. According to the industry distribution chart, Proteomics International Laboratories ranks #551 out of 804 companies in the Biotechnology industry, placing it in the top 68.5%.
Is Proteomics International Laboratories' Net Cash per Share too high?
Proteomics International Laboratories' current Net Cash per Share of $0.02 is 100% below median its 10-year median of 23.44. Over the past 10 years, this metric has ranged from a low of 5.42 to a high of 42.00. The Biotechnology industry median Net Cash per Share is 5.34. Proteomics International Laboratories' value of $0.02 is 99.6% below this industry median. Based on the distribution chart, Proteomics International Laboratories ranks #551 out of 804 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Proteomics International Laboratories has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Proteomics International Laboratories' Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Proteomics International Laboratories ranks #551 out of 804 companies for Net Cash per Share. This places Proteomics International Laboratories in the lower half of its industry. The industry median Net Cash per Share is 5.34. Proteomics International Laboratories' value of $0.02 is 99.6% below this benchmark. Historically, Proteomics International Laboratories' own Net Cash per Share has ranged from 5.42 to 42.00 over the past decade. While the company's 10-year median is 23.44 vs. the industry median of 5.34, Proteomics International Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.34, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Proteomics International Laboratories's current Net Cash per Share of $0.02 is 99.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Proteomics International Laboratories and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteomics International Laboratories's current Net Cash per Share is $0.02, which is 100% below median its own 10-year median of 23.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteomics International Laboratories stock overvalued right now?
Proteomics International Laboratories (PIQLF) has a current Net Cash per Share of $0.02. The stock's GF Value™ is $0.66, compared to a current price of $0.26 — trading 60.6% below its estimated fair value. The current Net Cash per Share is $0.02, which is 100% below median its 10-year median of 23.44 and 99.6% below the Biotechnology industry median of 5.34. Proteomics International Laboratories' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Proteomics International Laboratories (PIQLF), the current Net Cash per Share is $0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Proteomics International Laboratories (PIQLF) Overvalued in 2026?
Based on GuruFocus' analysis, Proteomics International Laboratories stock appears to be undervalued.
The current stock price of $0.26 is trading 60.6% below its estimated GF Value™ of $0.66.
Key valuation signals for PIQLF:
Net Cash per Share: $0.02 (100% below median its 10-year median of 23.44)
GF Value™: $0.66 vs. price of $0.26 (60.6% below fair value)
Industry Position: 99.6% below the Biotechnology median (#551 of 804)
No single metric tells the full story. See the PIQLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Proteomics International Laboratories Business Description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
31GF Score
Get the complete analysis for PIQLF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PIQLF has been successfully added to your 
